Table 1.

Demographic and Clinical Data of 21 Liver Transplantation Recipients Receiving CZA for KPC-Producing Klebsiella pneumoniae Bacterial Infection

No.	Age(y) /Sex	Diagnosis	MELD Score/PELD Score	Procedure	Infection	SOFA Score	T from CRKP Onset to LT(d)	Carbapenemase	Prior Antibiotics	Source Control	Septic Shock	Sepsis	Prior Antibiotics Time (d)	T from CRKP Onset to CZA Initiation(d)	Concomitant Tx	Tx Duration (d)	M/O	C/O
1	48/M	HBV-LC	15	DDLT	BSI, IAI, PI	13	1	KPC-2	Initial: CPZ/SBT, CAZ, IMP, VAN, FOS, MEM, TGC; Second: MEM, POL	YES	YES	YES	32	10	Initial: MEM, second: POL+LEV+VAN	Initial: 6, Second:17	P	Die
2	45/M	HCC	7	DDLT	BSI, IAI	12	62	KPC-2	IMP, FOS, MEM, TGC, AMI, VAN, CAZ	YES	NO	YES	33	30	MEM	5	P	Die
3	54/M	HCV-LC	11	DDLT	BSI	17	3	KPC-2	CAZ	NO	NO	NO	5	3	MEM	19	E	Die
4	37/M	ACLF	35	DDLT	PI	15	1	KPC-2	CAZ, MEM, VAN	NO	NO	NO	13	10	VAN+LEV	8	P	Improve
5	41/M	ACLF	28	DDLT	IAI, PI	8	55	KPC-2	Initial: IMP Second: AMI, LEV, VAN, CPZ/SBT, PIP/TAZ	YES	NO	NO	36	1	Initial: MET; second: AZM+ MET	Initial:13, Second:10	P	Die
6	46/F	PLD	10	DDLT	CRBSI	2	6	KPC-2	MEM, TGC, VAN	NO	NO	NO	19	7	-	6	E	Improve
7	67/M	ACLF, ALD	21	DDLT	IAI, CRBSI	14	3	KPC-2	CAZ, IMP, VAN	YES	NO	NO	31	1	AZM	11	E	Improve
8	50/M	HBV-LC	18	DDLT	IAI	19	56	KPC-2	CPZ/SBT	YEA	NO	NO	9	6	AZM	9	E	Improve
9	65/M	HCC, HBV-LC	11	DDLT	BSI	5	81	KPC-2	CAZ	NO	NO	NO	4	1	-	9	E	Die
10	68/M	ACLF	24	DDLT	BSI, IAI, PI	15	3	KPC-2	Initial: MOX, LEV, CPZ/SBT, MEM Second: CPZ/SBT, TGC, VAN, MEM	YES	NO	YES	16	1	Initial:MEM, PIP/TAZ Second:-	Initial: 31 Second:4	P	Die
11	39/F	Wilson’s disease	32	DDLT	PI	14	5	KPC-2	CAZ, PIP/TAZ	NO	NO	NO	10	1	AZM	13	E	Improve
12	47/M	ACLF	41	DDLT	BSI, IAI	17	3	KPC-2	CAZ, LEV	YES	NO	NO	3	2	MEM	19	E	Improve
13	65/M	HCC	8	DDLT	BSI	8	4	KPC-2	CAZ, MET, CPZ/SBT	NO	NO	NO	5	4	-	11	E	Improve
14	59/M	HCC	6	DDLT	PI	9	45	KPC-2	MEM, MOX, LIN, VAN, IMP	NO	NO	NO	13	2	-	8	P	Die
15	55/M	ACLF	24	DDLT	PI	9	3	KPC-2	MEM, VAN, TGC	NO	NO	NO	5	1	MET, POL	13	E	Improve
16	19/M	Carol’s syndrome	20	LDLT	IAI	13	34	NDM-1	MEM, VAN, CPZ/SBT	YES	NO	NO	31	3	MET	10	P	Die
17	30/M	ACLF	35	DDLT	BSI	11	7	KPC-2	CPZ/SBT, TEI	NO	NO	NO	5	1	-	9	E	Improve
18	1/F	BA	23	LDLT	PI, IAI	12	3	NDM-1	PIP/TAZ, MEM, TGC, CPZ/SBT,	YES	YES	NO	27	26	-	3	P	Die
19	2/F	BA	7	LDLT	IAI	9	2	NDM-1	TEI, TGC, MEM, CPZ/SBT	YES	NO	NO	33	32	AZM	18	E	Improve
20	12/F	BA	28	DDLT	IAI	4	29	KPC-2	CEF, MEM, LNI, VAN, TGC,	YES	NO	NO	33	3	MET	14	E	Improve
21	0.5/F	BA	62	LDLT	IAI	7	7	NDM-1	MEM, TGC, CAZ	YES	NO	NO	37	9	-	7	E	Improve

Abbreviations: T, time; Tx, treatment; HBV-LC, hepatitis B-related liver cirrhosis; HCC, hepatocellular carcinoma; ACLF, acute-on-chronic liver failure; ALD, alcoholic liver disease; PLD, polycystic liver disease; BA, biliary atresia; DDLT, deceased donor liver transplantation; LDLT, living donor liver transplantation; BSI, bloodstream infection; VAP, ventilator-associated pneumonia; IAI, intraabdominal infection; CRBSI, catheter-related bloodstream infection; PI, pulmonary infection; AMI, amikacin; LIN, linezolid; POL, polymyxin; LEV, levofloxacin; MOX, moxifloxacin; AZM, aztreonam; CAZ, ceftazidime; MET, metronidazole; CPZ/SBT, cefoperazone-sulbactam; PIP/TAZ, piperacillin and tazobactam; LIN, linezolid; TEI, teicoplanin; CEF, cefepime; E, eradication; P, persistence; M/O, microbiological outcome; C/O, clinical outcome.